Posted in Clinical Data Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease April 7, 2026 PharmaTimes Subcutaneous delivery shows IVlevel efficacy in moderate to severe TED Clinical DataOphthalmologyRead full story